非霍奇金淋巴瘤患者血管内皮生长因子表达与预后的关系  

Expression of VEGF and its relationship with prognosis of non-Hodgkin's lymphoma patients

作　　者：毕作木 孙桂珍 周其锋[1] 师丽娜[1] 王娟[1] 耿岩[1] 李大鹏[1] 

机构地区：[1]潍坊医学院附属淄博市第一医院血液内科,淄博255200 [2]淄博市沂源县医院,淄博370323

出　　处：《中国肿瘤临床与康复》2013年第11期1217-1219,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨非霍奇金淋巴瘤患者血管内皮生长因子(VEGF)表达与预后的关系。方法选择62例非霍奇金淋巴瘤患者为观察组,选择同期门诊体检的50例健康者为对照组,比较两组VEGF和微血管密度(MVD)的差别及其与观察组患者预后的关系。结果观察组患者VEGF和MVD水平均显著高于对照组,差异有统计学意义(P=0.000);观察组患者VEGF阳性者3年生存率(41.9%)显著低于VEGF阴性者(89.5%),差异有统计学意义(P=0.001);观察组Ⅲ、Ⅳ期患者的VEGF和MVD水平显著高于Ⅰ、Ⅱ期患者,差异有统计学意义(P=0.000);侵袭性患者的VEGF和MVD水平显著高于惰性者,差异有统计学意义(P=0.000);随着国际预后指数(IPI)危险级别的升高,患者的VEGF和MVD水平逐渐升高,差异有统计学意义(P=0.000);化疗疗效稳定和进展患者的VEGF和MVD水平显著高于完全缓解和部分缓解患者,差异有统计学意义(P=0.000)。结论非霍奇金淋巴瘤患者的VEGF高表达与临床分期和病理分型相关,且对化疗疗效有一定预测价值。Objective To explore the expression of VEGF and its relationship with prognosis of non- Hodgkin＇s lymphoma. Methods Selected 62 cases with non-Hodgkin＇s lymphoma as observation group and 50 subjects of healthy person as control group. VEGF and MVD level were compared between two groups and their relationships with the prognosis of patients were analyzed in observation group. Results VEGF and MVD level were much higher in observation group than that in control group （ P = 0. 000） ; The 3 years survival rate in the patients with VEGF expression was much lower than the rate in those patients without VEGF expression（41.9% vs 89. 5% ,P =0. 001 ） ; Patients of clinical stage m and Ⅳ had higher lever of VEGF and MVD than those in stage Iandll（P =0. 000） ;The VEGF and MVD were much higher in aggressive lymphoma than that in indolent lymphoma （ P = 0. 000） ; VEGF and MVD level gradually increased from low to high risk of IPI grades patients （ P = 0. 000） ; SD ＋ PD patients had higher VEGF and MVD level compared with CR ＋ PR patients （P =0. 000）. Conclusions High expression of VEGF in non-Hodgkin＇s lymphoma is closely related to clinical stage and pathologieal type, and has predictive value for chemotherapeutic efficacy.

关 键 词：非霍奇金淋巴瘤 血管内皮生长因子 预后 

分 类 号：R733.1[医药卫生—肿瘤]